BACKGROUND: Additional drugs are needed for the treatment of cytomegalovirus (CMV) infection. Artesunate is an antimalarial drug that has activity against CMV in vitro and in a rodent model. Only a small number of case reports are available describing the clinical effects of artesunate on CMV infection, and these yielded inconsistent results. OBJECTIVE: To evaluate the effect of artesunate on CMV infection, using blood samples collected from children who participated in malaria treatment trials. STUDY DESIGN:Quantitative CMV DNA PCR was performed on dried blood spots collected from 494 Ugandan children, who were randomized either to artesunate plus amodiaquine or sulfadoxine-pyrimethamine plus amodiaquine for acute malaria infection. Poisson regression was used to compare treatment regimens with respect to the change in the frequency and quantity of CMV detected that occurred before and after treatment. RESULTS:CMV was detected in 11.4% of children immediately prior to treatment and 10.7% 3 days later (p=0.70). The average quantity of CMV was 0.30 log10 copies per million cells higher on day 3 than at treatment initiation (95% CI 0.01-0.58, p=0.041). There was no measurable difference in either the frequency or quantity of CMV detected in blood between children randomized to the two treatment arms. CONCLUSIONS: A standard 3-day artesunate-containing antimalarial regimen had no detectable effect on CMV viremia in children with malaria. Longer treatment courses and/or higher doses of artesunate than those routinely used for malaria may be required for effective treatment of CMV infection.
RCT Entities:
BACKGROUND: Additional drugs are needed for the treatment of cytomegalovirus (CMV) infection. Artesunate is an antimalarial drug that has activity against CMV in vitro and in a rodent model. Only a small number of case reports are available describing the clinical effects of artesunate on CMV infection, and these yielded inconsistent results. OBJECTIVE: To evaluate the effect of artesunate on CMV infection, using blood samples collected from children who participated in malaria treatment trials. STUDY DESIGN: Quantitative CMV DNA PCR was performed on dried blood spots collected from 494 Ugandan children, who were randomized either to artesunate plus amodiaquine or sulfadoxine-pyrimethamine plus amodiaquine for acute malaria infection. Poisson regression was used to compare treatment regimens with respect to the change in the frequency and quantity of CMV detected that occurred before and after treatment. RESULTS: CMV was detected in 11.4% of children immediately prior to treatment and 10.7% 3 days later (p=0.70). The average quantity of CMV was 0.30 log10 copies per million cells higher on day 3 than at treatment initiation (95% CI 0.01-0.58, p=0.041). There was no measurable difference in either the frequency or quantity of CMV detected in blood between children randomized to the two treatment arms. CONCLUSIONS: A standard 3-day artesunate-containing antimalarial regimen had no detectable effect on CMV viremia in children with malaria. Longer treatment courses and/or higher doses of artesunate than those routinely used for malaria may be required for effective treatment of CMV infection.
Authors: Michael Boeckh; MeeiLi Huang; James Ferrenberg; Terry Stevens-Ayers; Laurence Stensland; W Garrett Nichols; Lawrence Corey Journal: J Clin Microbiol Date: 2004-03 Impact factor: 5.948
Authors: Sarah G Staedke; Arthur Mpimbaza; Moses R Kamya; Bridget K Nzarubara; Grant Dorsey; Philip J Rosenthal Journal: Lancet Date: 2004 Nov 27-Dec 3 Impact factor: 79.321
Authors: Suzanne J F Kaptein; Thomas Efferth; Martina Leis; Sabine Rechter; Sabrina Auerochs; Martina Kalmer; Cathrien A Bruggeman; Cornelis Vink; Thomas Stamminger; Manfred Marschall Journal: Antiviral Res Date: 2005-11-21 Impact factor: 5.970
Authors: A Asberg; A Humar; H Rollag; A G Jardine; H Mouas; M D Pescovitz; D Sgarabotto; M Tuncer; I L Noronha; A Hartmann Journal: Am J Transplant Date: 2007-07-19 Impact factor: 8.086
Authors: F M Mattes; E G Hainsworth; A F Hassan-Walker; A K Burroughs; P Sweny; P D Griffiths; V C Emery Journal: J Infect Dis Date: 2004-11-29 Impact factor: 5.226
Authors: Michael Y Shapira; Igor B Resnick; Sunwen Chou; Avidan U Neumann; Nell S Lurain; Thomas Stamminger; Orit Caplan; Niveen Saleh; Thomas Efferth; Manfred Marschall; Dana G Wolf Journal: Clin Infect Dis Date: 2008-05-01 Impact factor: 9.079
Authors: Grant Dorsey; Sarah Staedke; Tamara D Clark; Denise Njama-Meya; Bridget Nzarubara; Catherine Maiteki-Sebuguzi; Christian Dokomajilar; Moses R Kamya; Philip J Rosenthal Journal: JAMA Date: 2007-05-23 Impact factor: 56.272
Authors: Sujayita Roy; Ran He; Arun Kapoor; Michael Forman; Jennifer R Mazzone; Gary H Posner; Ravit Arav-Boger Journal: Antimicrob Agents Chemother Date: 2015-04-13 Impact factor: 5.191